Profile data is unavailable for this security.
About the company
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is engaged in advancing cancer therapies based on deoxyribonucleic acid (DNA)-damage response technologies. The Company has a pipeline of DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials and obtain marketing approval for cancer therapeutics. The Company’s research programs include kt-2000, kt-3000 and kt-4000. The kt-2000 next generation PARP-inhibitors. The kt-3000 class drug candidates are rationally designed to overcome treatment resistance by selectively downregulating DNA double-strand (DSB) repair mechanisms while enhancing PARP inhibitor activity. The kt-4000 series lead candidates release a potent methylation agent causing damage to a tumor cell’s DNA while also inhibiting DNA-damage repair mechanisms to cancer cell death.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.72m
- Incorporated2019
- Employees--
- LocationRakovina Therapeutics Inc105 - 1008 Beach AvenueVancouver V6E 1T7CanadaCAN
- Phone+1 (604) 619-0225
- Fax+1 (604) 980-6264
- Websitehttps://www.rakovinatherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appili Therapeutics Inc | 1.15m | -5.34m | 5.46m | 8.00 | -- | -- | -- | 4.75 | -0.044 | -0.044 | 0.0095 | -0.0811 | 0.5047 | -- | 2.12 | -- | -234.31 | -117.41 | -- | -173.66 | -- | -- | -464.23 | -3,037.15 | -- | -5.32 | -- | -- | -75.97 | -- | 63.20 | -- | -43.04 | -- |
| Rakovina Therapeutics Inc | 0.00 | -2.72m | 5.96m | -- | -- | 2.03 | -- | -- | -0.039 | -0.039 | 0.00 | 0.042 | 0.00 | -- | -- | -- | -53.46 | -- | -56.12 | -- | -- | -- | -- | -- | -- | -16.52 | 0.3151 | -- | -- | -- | 6.39 | -- | -- | -- |
| Titan Medical Inc | 24.14m | 11.94m | 6.27m | 4.00 | 0.6868 | 1.21 | 0.5165 | 0.2598 | 0.0801 | 0.0801 | 0.1959 | 0.0455 | 3.14 | -- | -- | 6,035,434.00 | 155.31 | -113.26 | 8,034.10 | -793.56 | -- | -- | 49.44 | -201.89 | -- | -- | 0.2424 | -- | -- | -- | 116.34 | -- | -12.72 | -- |
| Therma Bright Inc | 25.80k | -2.88m | 6.32m | -- | -- | 3.44 | -- | 244.90 | -0.0115 | -0.0115 | 0.0001 | 0.0058 | 0.0076 | 0.0023 | 0.115 | -- | -84.40 | -220.66 | -165.23 | -444.57 | 98.45 | -- | -11,152.48 | -10,853.16 | 0.0447 | -184.52 | 0.0411 | -- | -82.86 | 11.13 | 35.93 | -- | 40.15 | -- |
| Good Shroom Co Inc | 4.07m | -35.66k | 6.85m | -- | -- | 11.12 | -- | 1.69 | -0.0007 | -0.0007 | 0.0814 | 0.0121 | 2.46 | 5.66 | 6.99 | -- | -2.15 | -- | -5.42 | -- | 27.49 | -- | -0.8769 | -- | 1.01 | -5.28 | 0.0971 | -- | 160.30 | -- | 72.24 | -- | -- | -- |
